- Report
- February 2024
- 250 Pages
Global
From €4865EUR$5,000USD£4,168GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1459EUR$1,500USD£1,250GBP
- Report
- December 2020
- 60 Pages
Global
From €3162EUR$3,250USD£2,709GBP
- Report
- September 2022
- 283 Pages
Global
From €7297EUR$7,500USD£6,251GBP
- Report
- October 2022
- 80 Pages
Europe
From €3649EUR$3,750USD£3,126GBP
- Report
- September 2022
- 82 Pages
Turkey
From €3260EUR$3,350USD£2,792GBP
- Drug Pipelines
- June 2020
- 98 Pages
Global
From €1946EUR$2,000USD£1,667GBP
- Drug Pipelines
- December 2019
- 54 Pages
Global
From €3405EUR$3,500USD£2,917GBP
- Report
- January 2021
- 149 Pages
China, Global
From €3000EUR$3,303USD£2,660GBP
- Report
- November 2022
- 77 Pages
Global
From €1946EUR$2,000USD£1,667GBP
Anakinra is a recombinant human interleukin-1 receptor antagonist (IL-1Ra) used to treat a variety of immune disorders. It is a biologic drug, meaning it is derived from living cells, and is used to reduce inflammation in the body. Anakinra is used to treat rheumatoid arthritis, juvenile idiopathic arthritis, and other conditions caused by an overactive immune system. It is also used to treat symptoms of gout, such as joint pain and swelling.
Anakinra is administered as an injection, usually once a day. It works by blocking the action of interleukin-1, a protein that is involved in inflammation. By blocking the action of interleukin-1, Anakinra reduces inflammation and helps to relieve pain and swelling.
The Anakinra market is a growing sector of the immune disorders drugs market. It is a competitive market, with several companies offering Anakinra products. Some of the companies in the Anakinra market include Amgen, Pfizer, and Biogen. Show Less Read more
